Replies to post #594216 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

poly-iclc trial that started in 2010 was nGBM and rGBM. I don't think we can say with any sort of certainty that it would only apply to rGBM. Based on what we currently know, I'd say it applies to both.

[ATLnsider]

I hope eventually DCVax-L along with poly-ICLC (as an in vivo maturation and activation agent) + PD-1 inhibitor + CSF-1R inhibitor will be used to treat both newly diagnosed and recurrent GBM.

Also, my hope is that in the recurrent setting, a new DCVax-L vaccine is made from the new tumor.